Scleroderma News and Research RSS Feed - Scleroderma News and Research

Scleroderma is a chronic, often progressive, autoimmune disease in which the body's immune system attacks its own body. The disease, which literally means "hard skin," can cause a thickening and tightening of the skin. In some cases it causes serious damage to internal organs including the lungs, heart, kidneys, esophagus and gastrointestinal tract. Some medicines and treatments can help with certain symptoms, but there is still no cure for scleroderma, which affects about 300,000 nationwide. (By way of comparison, about 50,000 people have muscular dystrophy, 250,000 are estimated to have lupus and 350,000 have multiple sclerosis.)
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
Study opens up possibility of developing potential hormone therapies for SSc skin disease

Study opens up possibility of developing potential hormone therapies for SSc skin disease

The results of a study presented today at the European League Against Rheumatism Annual Congress showed for the first time a beneficial effect of oestrogens in experimental models of skin fibrosis that are representative of the disease process in systemic sclerosis (SSc). [More]
Implantable loop recorder can help diagnose heart rhythm abnormalities in SSc patients

Implantable loop recorder can help diagnose heart rhythm abnormalities in SSc patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that use of an easy to insert heart monitor in patients with systemic sclerosis (SSc) and no known heart disease enables early detection and treatment of potentially fatal cardiac arrhythmias. [More]

Nonprofits partner to raise awareness of scleroderma

If you've ever silently questioned someone wearing mittens on a warm spring day, the answer may be scleroderma. Or wondered why a woman, who otherwise appeared middle-aged, wore a face as wrinkle-free as her teenage daughter. The answer may be scleroderma. [More]
New BSR report sets roadmap to enhance care for individuals with rare rheumatic and musculoskeletal conditions

New BSR report sets roadmap to enhance care for individuals with rare rheumatic and musculoskeletal conditions

The British Society for Rheumatology has today launched a report setting out a programme of work to enhance care for people with rare rheumatic and musculoskeletal conditions. [More]
M10 peptide could help protect systemic sclerosis patients against fibrotic damage

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication. [More]
Complete genetic map of scleroderma opens door for diagnosis and targeted treatment

Complete genetic map of scleroderma opens door for diagnosis and targeted treatment

Scleroderma is an autoimmune disease that affects one out of every 10,000 people in Europe and North America, mostly middle-aged women, and causes death in a high percentage of cases. [More]
Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body [More]
African-American patients with connective tissue diseases at risk for cardiovascular disease

African-American patients with connective tissue diseases at risk for cardiovascular disease

A study based on medical records from more than a quarter million adult patients found that African-American patients with connective tissue diseases such as lupus or rheumatoid arthritis were twice as likely as white patients to suffer from narrowed or atherosclerotic blood vessels, which increase the risk of a heart attack, stroke or death. [More]
Antiscarring paste can halt fibrosis caused by radiation treatment

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB. [More]
Stem cell therapy not significantly better than conventional treatment for Crohn's disease

Stem cell therapy not significantly better than conventional treatment for Crohn's disease

A clinical trial to test the effectiveness of a stem cell therapy among adults with difficult to treat Crohn's disease has found it is not significantly better than conventional treatment in producing sustained disease remission after one year. [More]
Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS (Safety and Efficacy ofNintedanib in Systemic SClerosIS) study. [More]
Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10. [More]
Approval to start trial of Videregen's replacement trachea technology

Approval to start trial of Videregen's replacement trachea technology

The INSPIRE consortium, led by Videregen Ltd, has received approval from the MHRA1 to start a UK clinical trial with its tissue engineered replacement trachea. [More]
Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco. [More]
Algorithm reduces PAH screening costs in systemic sclerosis patients

Algorithm reduces PAH screening costs in systemic sclerosis patients

The Australian Scleroderma Interest Group has derived a screening algorithm for pulmonary arterial hypertension in patients with systemic sclerosis that saves costs by reducing the need for transthoracic echocardiography and right heart catheterisation. [More]
Robert Wood Johnson Medical Group physicians selected for Best Doctors in America List for 2015-2016

Robert Wood Johnson Medical Group physicians selected for Best Doctors in America List for 2015-2016

Sixty-one physicians affiliated with Robert Wood Johnson Medical Group, the faculty practice of Rutgers Robert Wood Johnson Medical School, were selected for the Best Doctors in America® List for 2015-2016. Only 5 percent of physicians in the United States earn this prestigious honor, determined by impartial peer review. [More]
Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus Biotherapeutics today announced that they have entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are an important class of proteins that play a key role in the innate immune system. [More]
Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan, plc. today announced that the company has received approval from the U.S. Food and Drug Administration to market 28 additional styles of Natrelle 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. [More]
Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Anticentromere and isolated nucleolar autoantibodies are prevalent in systemic sclerosis patients with pulmonary arterial hypertension, but they do not predict survival, US research shows. [More]
Advertisement